Rhumbline Advisers increased its stake in Stryker Corporation (NYSE:SYK) by 7.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 649,696 shares of the medical technology company’s stock after buying an additional 46,914 shares during the quarter. Rhumbline Advisers owned approximately 0.17% of Stryker Corporation worth $92,270,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC acquired a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $111,000. Motco boosted its holdings in shares of Stryker Corporation by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after buying an additional 278 shares during the last quarter. Bollard Group LLC boosted its holdings in shares of Stryker Corporation by 0.4% in the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after buying an additional 3 shares during the last quarter. Bruderman Asset Management LLC acquired a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $150,000. Finally, James Investment Research Inc. acquired a new stake in shares of Stryker Corporation in the 2nd quarter valued at approximately $155,000. 74.15% of the stock is owned by institutional investors.
SYK has been the subject of several research reports. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $148.00 price target on shares of Stryker Corporation in a report on Thursday, August 24th. Needham & Company LLC raised Stryker Corporation from an “underperform” rating to a “hold” rating in a report on Friday, August 25th. Zacks Investment Research raised Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target for the company in a report on Monday, July 17th. BidaskClub downgraded Stryker Corporation from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Stifel Nicolaus raised their price target on Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the stock. Stryker Corporation currently has an average rating of “Hold” and a consensus price target of $151.52.
In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $155.34, for a total transaction of $776,700.00. Following the sale, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 7.40% of the company’s stock.
Stryker Corporation (NYSE SYK) traded down $2.14 during trading hours on Monday, hitting $154.48. The stock had a trading volume of 1,267,200 shares, compared to its average volume of 1,183,556. The company has a market capitalization of $58,100.00, a PE ratio of 24.48, a P/E/G ratio of 2.43 and a beta of 0.79. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $160.62.
Stryker Corporation (NYSE:SYK) last released its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.39 earnings per share. equities analysts forecast that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Stryker Corporation (SYK) Stake Raised by Rhumbline Advisers” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/11/13/stryker-corporation-syk-stake-raised-by-rhumbline-advisers.html.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.